Protocol Ledger

NCT06592924 · Phase III · RECRUITING

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Interventional Phase III clinical trial protocol NCT06592924 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-28 Enrollment: 830 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06592924
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)830 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06592924
Protocol FieldVerified Registry Value
NCT IdentifierNCT06592924
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment830 participants (ESTIMATED)
Registered Start Date2025-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI